SCHEMBL23914964

SCHEMBL23914964

CC1(C)O[C@@H]2[C@H](O1)C(CO)O[C@H]2n1cnc2c(Cl)nc(Cl)nc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.65
TP53 P04637 2/20 0.65
PI4KA P42356 1/20 0.62
PI4K2B Q8TCG2 1/20 0.62
PI4K2A Q9BTU6 1/20 0.62
PI4KB Q9UBF8 1/20 0.62
ALDH1A1 P00352 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
MAPT P10636 1/20 0.50
ADORA2A P29274 3/20 0.49
ADORA3 P0DMS8 2/20 0.49
ADORA1 P30542 2/20 0.49
PDE2A O00408 1/20 0.49
ADRA1A P35348 1/20 0.49
PDE4D Q08499 1/20 0.49
PDE3A Q14432 1/20 0.49
ADORA2B P29275 1/20 0.48
MEN1 O00255 1/20 0.48
CYP1A2 P05177 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17205571 1.00 LMNA (0.65) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL18493278 1.00 LMNA (0.65) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL9620376 0.90 PI4KA (0.61) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL260626 0.90 PI4KA (0.61) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL19387129 0.89 PI4KA (0.72) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL22757351 0.89 PI4KA (0.60) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL14075797 0.89 PI4KA (0.72) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL25354403 0.89 PI4KA (0.66) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL572470 0.89 PI4KA (0.72) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL7202481 0.89 PI4KA (0.72) LMNATP53PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591355-B2 CD73 inhibitors and uses thereof PELOTON THERAPEUTICS INC. (US) 2023-02-28 US disclosed
US-20210317150-A1 CD73 INHIBITORS AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11591355-B2 CD73 inhibitors and uses thereof ENTPD5, ENTPD1, ENTPD3 LMNA 2040/4885TP53 2592/4885PI4KA 2940/4885
US-20210317150-A1 CD73 INHIBITORS AND USES THEREOF ENTPD5, ENTPD1, NT5E LMNA 1815/4885TP53 3358/4885PI4KA 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.